Idecabtagene vicleucel for relapsed/refractory multiple myeloma : a review of recent advances
Copyright 2022 Clarivate Analytics..
The introduction of new classes of drugs for the treatment of multiple myeloma (MM) in the past 2 decades, such as proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies, coupled with autologous stem cell transplantation, has approximately doubled the 5-year survival rate of MM patients. However, the patients eventually relapse and/or become resistant to the drugs and treatment. The recent emergence of anti-B-cell maturation antigen (BCMA) therapies, especially chimeric antigen receptor T-cell (CAR-T) immunotherapy targeting BCMA, holds great prospect in MM treatment. In this article, we review in detail the advances of idecabtagene vicleucel (ide-cel, bb-2121), the first CAR-T therapy targeting BCMA for treating relapse or refractory MM approved by the U.S. Food and Drug Administration (FDA) in 2021, including the preclinical study and phase I and II clinical trials. Also, it is predicted in this review that despite its amazing clinical efficacy and relatively lower toxicity, a lot of challenges and unsolved problems for ide-cel therapy remain in the way ahead.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 58(2022), 3 vom: 15. März, Seite 117-132 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tu, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2022.58.3.3381592 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338054537 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338054537 | ||
| 003 | DE-627 | ||
| 005 | 20231225235815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2022.58.3.3381592 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM338054537 | ||
| 035 | |a (NLM)35274631 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tu, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Idecabtagene vicleucel for relapsed/refractory multiple myeloma |b a review of recent advances |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 14.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2022 Clarivate Analytics. | ||
| 520 | |a The introduction of new classes of drugs for the treatment of multiple myeloma (MM) in the past 2 decades, such as proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies, coupled with autologous stem cell transplantation, has approximately doubled the 5-year survival rate of MM patients. However, the patients eventually relapse and/or become resistant to the drugs and treatment. The recent emergence of anti-B-cell maturation antigen (BCMA) therapies, especially chimeric antigen receptor T-cell (CAR-T) immunotherapy targeting BCMA, holds great prospect in MM treatment. In this article, we review in detail the advances of idecabtagene vicleucel (ide-cel, bb-2121), the first CAR-T therapy targeting BCMA for treating relapse or refractory MM approved by the U.S. Food and Drug Administration (FDA) in 2021, including the preclinical study and phase I and II clinical trials. Also, it is predicted in this review that despite its amazing clinical efficacy and relatively lower toxicity, a lot of challenges and unsolved problems for ide-cel therapy remain in the way ahead | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-B-cell maturation antigen (BCMA) agents | |
| 650 | 4 | |a CAR-T therapy | |
| 650 | 4 | |a Cancer immunotherapy | |
| 650 | 4 | |a Cell-based gene therapy | |
| 650 | 4 | |a Hematologic malignancies | |
| 650 | 4 | |a Idecabtagene vicleucel (ide-cel) | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a idecabtagene vicleucel |2 NLM | |
| 650 | 7 | |a 8PX1X7UG4D |2 NLM | |
| 700 | 1 | |a Xiao, Yajuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yadong |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Rongcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhe-Sheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 58(2022), 3 vom: 15. März, Seite 117-132 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2022 |g number:3 |g day:15 |g month:03 |g pages:117-132 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2022.58.3.3381592 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2022 |e 3 |b 15 |c 03 |h 117-132 | ||